Blockchain Registration Transaction Record

Quantum BioPharma's MS Drug Advances with Key Study Results

Quantum BioPharma announces positive 90-day toxicity study results for Lucid-MS, supporting IND application for Phase 2 MS clinical trial targeting demyelination reversal.

This development represents a potential breakthrough for the approximately 2.8 million people worldwide living with Multiple Sclerosis. Current MS treatments primarily focus on managing symptoms and reducing relapse rates, but Lucid-MS targets the fundamental cause of the disease—demyelination. If successful in clinical trials, this could become the first treatment capable of reversing nerve damage in MS patients, potentially restoring neurological function and dramatically improving quality of life. For the biopharmaceutical industry, it demonstrates progress in developing treatments for neurodegenerative conditions that have historically been difficult to treat effectively.